Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8OWT

SARS-CoV-2 spike RBD with A8 and H3 nanobodies bound

This is a non-PDB format compatible entry.
Summary for 8OWT
Entry DOI10.2210/pdb8owt/pdb
DescriptorNanobody A8, Spike protein S1, Nanobody H3, ... (6 entities in total)
Functional Keywordsnanobody, complex, receptor binding domain, sars-cov-2, viral protein
Biological sourceLama glama
More
Total number of polymer chains6
Total formula weight107302.55
Authors
Mikolajek, H.,Naismith, J.H.,Owens, R.J. (deposition date: 2023-04-28, release date: 2024-05-08, Last modification date: 2024-11-06)
Primary citationCornish, K.,Huo, J.,Jones, L.,Sharma, P.,Thrush, J.W.,Abdelkarim, S.,Kipar, A.,Ramadurai, S.,Weckener, M.,Mikolajek, H.,Liu, S.,Buckle, I.,Bentley, E.,Kirby, A.,Han, X.,Laidlaw, S.M.,Hill, M.,Eyssen, L.,Norman, C.,Le Bas, A.,Clarke, J.,James, W.,Stewart, J.P.,Carroll, M.,Naismith, J.H.,Owens, R.J.
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Open Biology, 14:230252-230252, 2024
Cited by
PubMed Abstract: The Omicron strains of SARS-CoV-2 pose a significant challenge to the development of effective antibody-based treatments as immune evasion has compromised most available immune therapeutics. Therefore, in the 'arms race' with the virus, there is a continuing need to identify new biologics for the prevention or treatment of SARS-CoV-2 infections. Here, we report the isolation of nanobodies that bind to the Omicron BA.1 spike protein by screening nanobody phage display libraries previously generated from llamas immunized with either the Wuhan or Beta spike proteins. The structure and binding properties of three of these nanobodies (A8, H6 and B5-5) have been characterized in detail providing insight into their binding epitopes on the Omicron spike protein. Trimeric versions of H6 and B5-5 neutralized the SARS-CoV-2 variant of concern BA.5 both and in the hamster model of COVID-19 following nasal administration. Thus, either alone or in combination could serve as starting points for the development of new anti-viral immunotherapeutics.
PubMed: 38835241
DOI: 10.1098/rsob.230252
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.37 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon